Designing subtype-selective agonists for neuronal nicotinic acetylcholine receptors is a challenging and significant goal aided by intricate knowledge of each subtype's binding patterns. We previously reported that in α6β2 receptors, acetylcholine makes a functional cation-π interaction with Trp149, but nicotine and TC299423 do not, suggesting a distinctive binding site. This work explores hydrogen binding at the backbone carbonyl associated with α6β2 Trp149. Substituting residue i + 1, Thr150, with its α-hydroxy analogue (Tah) attenuates the carbonyl's hydrogen bond accepting ability. At α6(T150Tah)β2, nicotine shows a 24-fold loss of function, TC299423 shows a modest loss, and acetylcholine shows no effect. Nicotine was further analyzed via a double-mutant cycle analysis utilizing N'-methylnicotinium, which indicated a hydrogen bond in α6β2 with a ΔΔG of 2.6 kcal/mol. Thus, even though nicotine does not make the conserved cation-π interaction with Trp149, it still makes a functional hydrogen bond to its associated backbone carbonyl.
The neuronal nicotinic acetylcholine receptors (nAChRs) make up a group of pentameric ligand-gated ion channels (pLGICs) typically found at presynaptic terminals, where they modulate neurotransmitter release. [1] [2] [3] There are 11 known subunits (α2-α7, α9, α10, and β2-β4) that assemble into pentamers in different combinations. 4 The different subunits share a common topology, and the agonist binding site is found in the extracellular binding region at the interface of two subunits. Different subunit combinations, i.e., different nAChR subtypes, display distinctive functions, pharmacologies, and localizations. 5 While several subtypes are distributed throughout the brain (e.g., α4β2 and α7), others are concentrated in specific regions and expressed by only certain cell types. 6, 7 The α6-containing subtypes follow the latter pattern and are prominently expressed in dopaminergic neurons of the ventral tegmental area and the substantia nigra pars compacta, making them promising targets for both Parkinson's disease and addiction. [8] [9] [10] In addition, the α6 subunit is expressed in dorsal root ganglia, where it plays an important role in mechanical allodynia associated with neuropathies and inflammatory injuries. 11 As such, insights into strategies for targeting drugs specifically to α6-containing nAChRs would be quite valuable.
Mapping the binding interface is a major step toward that goal. A growing collection of structural data has provided valuable guidance, but it has been less helpful in revealing the subtle features that distinguish particular subtypes. For prototype agonists such as ACh and nicotine (structures shown in Figure 1A ), the residues comprising the primary and complementary binding interfaces are conserved among all α and all β subunits, respectively. 12 Therefore, additional precision is required to understand the functional details of neuronal nAChR binding sites. 13 We have established a strategy based on the incorporation of noncanonical amino acids and electrophysiological characterization that allows high-precision characterization of drug-receptor interactions in nAChRs and related systems. 14 Application of this approach to the α4β2 nAChR, the most common nicotinic receptor in the brain, revealed three key binding interactions: a cation-πinteraction with α4
Trp149, a hydrogen bond with the backbone carbonyl associated with Trp149, and an additional hydrogen bond between nicotine's pyridine nitrogen and a backbone NH in the β2 subunit. 15, 16 The cation-π interaction at Trp149, which is also termed TrpB as it lies on canonical "loop B" of the primary agonist binding site, has been observed at homologous aromatic residues throughout the nAChR and broader pLGIC families and was later corroborated in recent crystal structures of α4β2 nAChR, glycine, and serotonin receptors. [17] [18] [19] [20] [21] However, recent work using noncanonical amino acid mutagenesis has shown that in the α6β2 receptor, acetylcholine makes a functionally important cation-π interaction, but nicotine and TC299423 [an agonist that shows some selectivity for α6β2 receptors 22 (structure shown in Figure 1A) ] do not. 23 This binding mode differs from that of the α4β2 subtype, which suggests the question of what interactions besides a cation-π interaction at Trp149 might be responsible for the binding of nicotine and TC299423 in the α6β2 nAChR.
This report investigates the role of a possible hydrogen bond between an agonist's amine moiety and the backbone carbonyl associated with TrpB in α6β2. While quaternary ammonium agonists such as acetylcholine cannot make a hydrogen bond, such interactions have been observed in α4β2 for nicotine and the smoking cessation drugs varenicline (Chantix) and cytisine (Tabex), 24, 25 all of which contain a protonated amine (ammonium ion) that provides the hydrogen bond donor. In each of those instances, evidence of the hydrogen bond was accompanied by evidence of a cation-π interaction at TrpB; however, because nicotine was not observed to make a strong cation-π interaction at TrpB with α6β2, it was uncertain whether it would make the corresponding hydrogen bond with that tryptophan's backbone carbonyl. Here, structure-function studies using α-hydroxy acid substitution reveal that nicotine indeed makes a functional hydrogen bond with this backbone carbonyl in α6β2. The interaction is further supported and quantified by a doublemutant cycle analysis utilizing N'-methylnicotinium. In contrast, TC299423 shows at best a weak interaction with this carbonyl
RESULTS AND DISCUSSION
α-Hydroxy Acid Substitution at Thr150 in α6β2 ‡ .
All studies make use of the previously described α6β2 ‡ construct, which contains mutations far removed from the agonist binding site that increase plasma membrane levels, in part, by facilitating transport from the endoplasmic reticulum to the cell surface. 23 To probe for a hydrogen bond to a backbone carbonyl, residue i + 1 is mutated to the corresponding α-hydroxy acid ( Figure 1B ). 26 In both α6β2 ‡ and α4β2, residue i + 1 to Trp149 is Thr150. In the mutation to threonine α-hydroxy acid (Tah), the amide backbone becomes an ester backbone without affecting the side chain ( Figure 1C ). It is well established that an ester carbonyl is a significantly weaker hydrogen bond acceptor than an amide carbonyl is. 27 In previous studies of several nAChR subtypes, this mutation has produced shifts in EC 50 ranging from 3-to 27-fold. 13 The results of substituting α6 Thr150 with Tah are summarized in Table 1 . Importantly, ACh, which cannot make a conventional hydrogen bond to the backbone carbonyl, shows no significant effect. This establishes that the function of the receptor has not been degraded in some generic fashion by the backbone mutation. In sharp contrast, nicotine displays a 24-fold increase in EC 50 (loss of function, dose responses shown in Figure 1D ), suggesting it makes a potent hydrogen bond with the backbone carbonyl of TrpB. Perhaps surprisingly, only a 4-fold loss of function was observed for TC299423.
Quantifying the α6β2*-Nicotine Hydrogen Bond.
Our results show that perturbing the backbone carbonyl at TrpB strongly impacts nicotine activation of the α6β2 ‡ receptor. This is highly suggestive of a hydrogen bond, but other explanations are possible. Also, putting an energetic value on the proposed hydrogen bond is challenging. A classic technique in determining a functional coupling interaction between amino acids in a protein is double-mutant cycle analysis. [28] [29] [30] In this type of experiment, the two amino acids of interest are each mutated in a way that would attenuate the proposed interaction, both independently (as single mutants) and simultaneously (as a double mutant). If the change in binding seen in the double mutant is a simple sum of each single mutantthat is, if the energetic effects are additive-the single-mutant perturbations act independently of each other, and the two amino acids do not participate in a functionally coupled interaction. If, on the other hand, the effect of the double mutant proves to be nonadditive, the amino acids are considered to be functionally coupled. The degree to which the double mutant is additive or nonadditive is expressed by an Ω value, which is defined as the product of the wild-type and double-mutant EC 50 values divided by the product of the single-mutant EC 50 values (Figure 2 ). An Ω value differing from 1 indicates functional coupling between amino acids. As discussed elsewhere, perturbations to EC 50 resulting from mutations at the agonist binding site can be considered to reflect changes in agonist binding affinities, allowing an Ω valueto be converted to a ΔΔΟ for the coupling energy between amino acids. 29, [31] [32] [33] To assess the nicotine hydrogen bond with the TrpB backbone carbonyl, we designed an analogue of double-mutant cycle analysis (schematic shown in Figure 2 ). The first mutant in the analysis is the T150Tah substitution that results in an amide-to-ester backbone mutation. The second "mutant" uses a nicotine analogue, wherein the pyrrolidine nitrogen is methylated to yield N'-methylnicotinium (N'MeNic in data tables). As a quaternary ammonium, this compound is similar to ACh in that it cannot donate a hydrogen bond. By determining EC 50 values for each condition (nicotine at the wild type, nicotine at T150Tah, N'-methylnicotinium at the wild type, and N'-methylnicotinium at T150Tah) and determining whether the double mutant shows an additive loss of function, this mutant cycle will not only further test the hypothesis that nicotine makes a hydrogen bond with the backbone carbonyl of Trp149 but also quantify the strength of the hydrogen bond. We have previously used a similar mutant cycle analysis, one mutation being on the protein the other on the drug, to probe the hydrogen bond involving the pyridine N of nicotine. 30 As a proof of concept, the double-mutant cycle analysis described above was first performed in the α4β2 nAChR, because this subtype is more extensively studied and has a better understood binding map for nicotine. At α4β2, nicotine shows a 27-fold shift in EC 50 at the T150Tah mutant, a major loss of function (Table 2 ). When N'-methylnicotinium is tested at the wild-type receptor, a 6-fold loss of function is observed. If these two mutations were independent of each other, meaning loss of function was due to an effect other than attenuating the proposed hydrogen bond, an additive loss of function would be expected at the double mutant close to 160-fold. Instead, an EC 50 of 0.40 μM is observed, which is not meaningfully different from the EC 50 of N'-methylnicotinium at the wild type (0.62 μM) and only a 4-fold loss of function compared to nicotine at the wild type. This lack of additivity is quantified with an Ω value of 42, which when expressed in free energy terms reveals a ΔΔG value of −2.2 kcal/mol. This value is comparable to empirically determined hydrogen bond strengths of N-methylacetamide aggregates in carbon tetrachloride (ΔΗ° = −4.2 kcal/mol) and benzene (ΔΗ° = −3.6 kcal/mol). 34, 35 The same approach was taken in α6β2*; as noted above, nicotine experiences a 24-fold loss of function at T150Tah. The other single mutant in this analysis, which is N'-methylnicotinium at wild-type α6β2 ‡ , shows an even larger loss of function, with a 38-fold shift in EC 50 . If these losses in function were not due to hydrogen bonding and instead were independent of each other, the double-mutant fold shift would be additive with a nearly 900-fold increase in EC 50 with respect to that of the wild type. The double mutant, N'-methylnicotinium at T150Tah, has instead an EC 50 of 1.2, μM, an 11-fold shift away from that of the wild type, showing the effect is nonadditive. Overall, the mutant cycle has an Ω value of 88 and a ΔΔG of −2.6 kcal/mol, suggesting nicotine makes a hydrogen bond in α6β2* that is at least as strong as that seen in α4β2.
CONCLUSION
These results reveal an interesting diversity among nAChR subtypes. First, consider the binding of nicotine at the two different receptor subtypes, α4β2 and α6β2. The binding pattern for α4β2 is familiar, a strong cation-π interaction with TrpB and a strong hydrogen bond to the associated backbone carbonyl. In α6β2, the cation-π interaction is absent, so one might conclude that the drug had moved away from TrpB. We now find that nicotine makes a comparably strong hydrogen bond to the backbone carbonyl in α6β2, a surprising and intriguing binding pattern. Another interesting difference is seen in the consequences of quaternizing nicotine, making it more like the natural agonist ACh. In α4β2, this has a modest effect on potency (an only 6-fold shift), but in α6β2, the impact is markedly larger (a 37-fold shift), again suggesting an altered binding orientation.
Finally, our results suggest that TC299423 interacts very weakly with TrpB. There is no evidence of a cation-π interaction, and a backbone mutation has an effect much smaller than that seen for nicotine. These findings should provide valuable guidance to efforts to develop subtype-specific drugs targeting α6-containing nAChRs.
MATERIALS AND METHODS

Molecular Biology.
Rat α6, α4, and β2 nAChRs were in the pGEMhe vector, a cDNA plasmid optimized for protein expression in Xenopus oocytes. Site-directed mutagenesis was performed by polymerase chain reaction using the Stratagene QuikChange protocol and primers ordered from Integrated DNA Technologies (Coralville, IA). Circular cDNA was linearized with SbfI (New England Biolabs, Ipswich, MA) and then transcribed in vitro using the T7 mMessage mMachine kit (Life Technologies, Santa Clara, CA), with a purification step after each process (Qiagen, Valencia, CA). Final concentrations were quantified by ultraviolet spectroscopy.
Ion Channel Expression and α-Hydroxy Acid Incorporation.
For optimized expression, α4L9'Aβ2 and α6L9'Sβ2L9'S LFM / AAQA were used as the "wildtype" receptor against which further mutations are compared. These are termed α4β2 and α6β2*, respectively, throughout for the sake of clarity. For nonsense suppression-based, sitespecific noncanonical amino acid incorporation, the cyanomethylester form of threonine α-hydroxy was first synthesized, coupled to the dinucleotide dCA, and enzymatically ligated to UAG suppressor 74-mer THG73 tRNA CUA as previously described. 13 The product was verified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry on a 3-hydrox-ypicolinic acid matrix. Xenopus laevis oocytes (stage V-VI) were sourced from both a Caltech facility and Ecocyte Bio Science (Austin, TX). The Tah-tRNA was injected along with T150UAG mRNA into oocytes in a 1:1 volume ratio, with an α6:β2 mRNA mass ratio of 10:1 or an α4:β2 mass ratio of 1:3, resulting in 25 ng each of mRNA and tRNA injected per cell. Cells were incubated for 24-48 h at 18 °C in an ND96 solution [96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , and 5 mM HEPES (pH 7.5)] enriched with theophylline, sodium pyruvate, gentamycin, and horse serum. The fidelity of incorporation of Tah was confirmed by charging tRNA with Thr in a wild-type recovery experiment. Data from these experiments (reported as Thr in Tables 1 and 2 ) matched wildtype data, reported in previous studies. A read-through/re-aminoacylation test serves as a negative control wherein a 76-mer tRNA is injected alongside mRNA. A lack of current proved there was no detectable reaminoacylation at the Thr150 site.
N'-Methylnicotinium Synthesis.
Synthesis of N'-methyl-nicotinium was based on previously reported methods. 36 All reagents were purchased from Sigma-Aldrich (St. Louis, MO). In a round-bottom flask, 19.8 mL of (-)-nicotine was added to 250 mL of acetonitrile and excess sodium carbonate. Then, 5.76 mL of methyl iodide was added dropwise while the mixture was being stirred. The reaction mixture was stirred at room temperature for 3 days. The reaction solution was filtered by vacuum, and solids were discarded. Solvent from the filtrate was removed by rotary evaporation until a tan oil remained. Deionized water (50 mL) was added to the oil and dissolved, forming an orange solution. Continuous chloroform extraction was performed on the orange solution for 5 days. The aqueous layer was isolated, and solvent was removed by rotary evaporation upon which crystals formed. The product was recrystallized three consecutive times with hot isopropanol for a yield of >40%. 
Whole-Cell Electrophysiological Characterization.
Acetylcholine chloride and (-)-nicotine tartrate were purchased from Sigma-Aldrich, while TC299423 (Targacept) was a generous gift. N'-Methylnicotinium iodide was prepared according to the procedure described above. Agonist-induced currents were recorded in twoelectrode voltage-clamp mode using the OpusXpress 6000A instrument (Molecular Devices, Sunnyvale, CA) at a holding potential of -60 mV in a running buffer of Ca 2 +-free ND96. Agonists were prepared in Ca 2 +-free ND96 and delivered to cells via a 1 mL application over 15 s followed by a 2 min wash. EC 50 values describe the concentration required to activate half the receptors expressed on the cell surface and were determined through doseresponse experiments, while fold shifts in EC 50 are equal to the mutant EC 50 divided by the wild-type EC 50 . To derive an EC 50 value, data from dose-response experiments were normalized to the maximal current response, averaged, and fit to the Hill equation using Kaleidagraph (Synergy Software, Reading, PA), though data are visualized here with Prism (GraphPad Software, La Jolla, CA). Error bars, as well as reported errors for EC 50 and the Hill coefficient (n H ), are presented as standard errors of the mean. Hydrogen Bonding at the α6β2* TrpB Carbonyl 
